Ikaika Therapeutics
Oak Park, US · Delaware corporation
Ikaika Therapeutics develops treatments for cardiovascular disease using genetic signals, with a focus on inherited forms of heart disease and neuromuscular genetic disorders such as myopathies and muscular dystrophy. The company applies research on the genetic causes and mechanisms of cardiac disorders to drive drug development.
Founders & leadership
EM
Elizabeth McNallyFounder, CEO & Board Member
CH
CHIH-KAO HUNamed on SEC filing
EM
ELIZABETH MCNALLYNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$1M disclosed across 1 round · 2021
▶$1MraisedNov 2021 · 1 investors · Other Health CareRule 506(b)
▶$1MraisedNov 2021 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- CHIH-KAO HUDirector
- ELIZABETH MCNALLYExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Ikaika Therapeutics do?
- Ikaika Therapeutics develops treatments for cardiovascular disease using genetic signals, with a focus on inherited forms of heart disease and neuromuscular genetic disorders such as myopathies and muscular dystrophy. The company applies research on the genetic causes and mechanisms of cardiac disorders to drive drug development.
- Who founded Ikaika Therapeutics?
- Ikaika Therapeutics was founded by Elizabeth McNally.
- How much funding has Ikaika Therapeutics raised?
- Ikaika Therapeutics has disclosed $1M raised across 1 round.
- Where is Ikaika Therapeutics headquartered?
- Ikaika Therapeutics is headquartered in Oak Park, US.